PIA
NBIX icon

Piedmont Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Piedmont Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-8,067
Closed -$698K – 459
2020
Q1 		$698K Buy
8,067
+1,264
+19% +$124K 0.03% 367
2019
Q4 		$731K Buy
6,803
+47
+0.7% +$4.92K 0.03% 412
2019
Q3 		$609K Buy
6,756
+77
+1% +$7.19K 0.02% 449
2019
Q2 		$564K Buy
6,679
+110
+2% +$9.03K 0.02% 499
2019
Q1 		$579K Buy
6,569
+95
+1% +$7.94K 0.02% 459
2018
Q4 		$462K Buy
6,474
+25
+0.4% +$2.4K 0.02% 488
2018
Q3 		$793K Buy
+6,449
New +$732K 0.03% 358

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Piedmont Investment Advisors's NBIX Position: Q2 2020 in Review

Piedmont Investment Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2020, closing a stake of 8,067 shares — an estimated $698K sold.

Piedmont Investment Advisors first reported a position in NBIX in Q3 2018 and held it in 7 quarters. The position peaked at $793K in Q3 2018. 419 funds tracked by Wall St. Rank hold NBIX as of Q2 2020.

  • Piedmont Investment Advisors reported no remaining Neurocrine Biosciences position as of Q2 2020 after selling out during the quarter.
  • Piedmont Investment Advisors sold 8,067 Neurocrine Biosciences shares in Q2 2020, an estimated $698K.
  • Piedmont Investment Advisors first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 7 quarters.
  • Piedmont Investment Advisors's Neurocrine Biosciences position peaked at $793K in Q3 2018.
  • 419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2020.

Based on Piedmont Investment Advisors's 13F filing for Q2 2020.